BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Table 2 Cox proportional hazards model for disease-free and overall survivals of 254 patients with EOC

DFS	Univariate HR (95% CI)^b	p	Multivariate HR (95% CI)^b	p	OS	Univariate HR (95% CI)^b	p	Multivariate HR (95% CI)^b	p
FIGO stage [advanced/early]	3.6 (2.2–5.8)	< 0.001	2.3 (1.3–4.2)	0.004	FIGO stage [advanced/early]	2.6 (1.3–4.8)	0.004	1.3 (0.6–2.7)	0.53
Histology [serous/non-serous^a]	1.5 (1.1–2.2)	0.01	1.1 (0.8–1.6)	0.63	Histology [serous/non-serous^a]	1.1 (0.7–1.7)	0.74
Tumor grade [3/1–2]	2.0 (1.1–3.4)	0.015	1.6 (0.9–2.8)	0.11	Tumor grade [3/1–2]	1.4 (0.7–2.9)	0.39
Postoperative residual tumor [≥1 cm/< 1 cm]	2.8 (2.1–3.9)	< 0.001	2.1 (1.4–2.9)	< 0.001	Postoperative residual tumor [> 1 cm/< 1 cm]	3.1 (2.0–5.0)	< 0.001	2.7 (1.6–4.7)	< 0.001
BTLA expression [detectable/non- detectable]	2.0 (1.4–2.9)	< 0.001	1.7 (1.2–2.4)	0.002	BTLA expression [detectable/non- detectable]	2.0 (1.2–3.5)	0.009	1.8 (1.04–3.0)	0.035

Abbreviations: EOC epithelial ovarian carcinoma; DFS disease-free survival; OS overall survival; HR Hazard ratio; CI confidence interval; FIGO International Federation of Gynecology and Obstetrics; BTLA B and T lymphocyte attenuator
^aNon-serous includes mucinous, clear cell, endometrioid, and undifferentiated types
^bCox regression model